Bristol Myers Squibb has announced that data from its cardiovascular portfolio will be presented at the American College of Cardiology’s 71st Annual Scientific Session, taking place in Washington, DC, and virtually, from April 2-4, 2022.
Data from clinical and real-world studies will be featured, including two late-breaking clinical trial presentations from the mavacamten development program, showcasing the company’s leading cardiovascular research and commitment to improving the lives of patients, BMS said in its press release.
The company announced key presentations:
A late-breaking clinical trial presentation of data from the Phase 3 VALOR-HCM study evaluating mavacamten in patients with obstructive hypertrophic cardiomyopathy (obstructive HCM) with severe symptoms referred for septal reduction therapy (SRT).
A late-breaking clinical trial presentation of updated interim results from baseline up to Week 84 of the EXPLORER-LTE cohort of the MAVA-LTE study, the largest and longest report of mavacamten in patients with symptomatic obstructive HCM.
An analysis of the EXPLORER-HCM study exploring the impact of mavacamten on a range of cardiopulmonary exercise test (CPET) parameters to characterize exercise capacity and submaximal exertional tolerance in symptomatic obstructive HCM patients.
Analysis of two-week patch electrocardiogram recordings from over 5,700 older U.S. primary care patients with previously undiagnosed atrial fibrillation (AF) in the GUARD-AF (ReducinG stroke by screening for UndiAgnosed atRial fibrillation in elderly inDividuals) study. This randomized controlled trial helps address the critically important need for further research on the impact of earlier detection of AF by a screening intervention, compared to usual care, on net clinical benefit, including reduction of stroke risk.
“This is an exciting time for our cardiovascular franchise, and our presence at ACC this year underscores our continued progress in the treatment of cardiovascular conditions,” said Roland Chen, M.D., senior vice president, head of cardiovascular development and global drug development at Bristol Myers Squibb. “We look forward to sharing these new data that reinforce the value of mavacamten as a potential treatment option for symptomatic obstructive HCM. We are also proud to continue our longstanding commitment to patients with atrial fibrillation by raising awareness of the significant need for further research on the impact of earlier detection of AF by a screening intervention.”